HC Wainwright & Co. Reiterates Buy on Longboard Pharmaceuticals, Maintains $60 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Patrick Trucchio has reiterated a Buy rating on Longboard Pharmaceuticals (NASDAQ:LBPH) and maintained a $60 price target.
April 16, 2024 | 2:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. reaffirms a Buy rating and a $60 price target on Longboard Pharmaceuticals.
The reiteration of a Buy rating and maintenance of a $60 price target by a reputable analyst firm like HC Wainwright & Co. typically signals strong analyst confidence in the company's future performance. This can positively influence investor sentiment and potentially lead to an increase in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100